We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Scientists Develop a Way to Make Drugs Safer

By Biotechdaily staff writers
Posted on 13 Sep 2002
Scientists have developed a way to safely turn on and off the effects of drugs. Their work was described in the September 5, 2002, issue of Nature.

The premise of the research was to develop an antidote that could be used in cases when patients have complications from a drug or when doctors believe a change of treatment is needed and they cannot wait for the effects of the drug to wear off naturally. The researchers, from Duke University Medical Center (Durham, NC, USA), used the drug heparin as a model. The ability to control the medication with an antidote would give surgeons more control over bleeding in patients during and after surgical procedures. Heparin can be controlled by an antidote called protamine but it does not always work.

The researchers focused on a class of drugs called aptamers, compound made of RNA that bind directly to a target protein and inhibit the protein's activity. "We developed an aptamer that inhibits a protein required for blood clotting to make a new anticoagulant. We then made an antidote specifically paired to the aptamer to reverse the blood-thinning process,” said Chris P. Rusconi, Ph.D., lead author of the study and director of Duke's Research Program in Combinatorial Therapeutics.

Using plasma samples from six patients who cannot tolerate heparin, the researchers showed that the newly created anticoagulant worked and that the antidote could reverse the blood-thinning effect of heparin. They said the antidote was effective within 10 minutes.




Related Links:
Duke University Medical Center

Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Turbidimetric Control
D-Dimer Turbidimetric Control

Latest BioResearch News

Genome Analysis Predicts Likelihood of Neurodisability in Oxygen-Deprived Newborns
13 Sep 2002  |   BioResearch

Gene Panel Predicts Disease Progession for Patients with B-cell Lymphoma
13 Sep 2002  |   BioResearch

New Method Simplifies Preparation of Tumor Genomic DNA Libraries
13 Sep 2002  |   BioResearch